XNCR logo

Xencor Inc. (XNCR)

$35.40

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on XNCR

Market cap

$2.66B

EPS

-1.59

P/E ratio

--

Price to sales

17.45

Dividend yield

--

Beta

0.785875

Price on XNCR

Previous close

$37.09

Today's open

$37.07

Day's range

$35.34 - $37.39

52 week range

$10.38 - $40.60

Profile about XNCR

CEO

Bassil I. Dahiyat

Employees

260

Headquarters

Pasadena, CA

Exchange

NASDAQ Global Market

Shares outstanding

75039689

Issue type

Common Stock

XNCR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on XNCR

Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis. The data are being presented in a poster session at the American College of Rheumatology (ACR) Convergence 2026 conference in.

news source

Business Wire • Nov 9, 2026

news preview

Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?

Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.

news source

Investors Business Daily • Nov 5, 2026

news preview

Xencor Reports Third Quarter 2026 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026. “Xencor's lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a mono.

news source

Business Wire • Nov 4, 2026

news preview

Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates

Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data

Xencor stock catapulted Monday to a nearly four-year high, briefly breaking out on positive results in kidney cancer.

news source

Investors Business Daily • Oct 26, 2026

news preview

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer

Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for planned late-stage development and expects to begin a registration-enabling study in 2027.

news source

MarketBeat • Oct 26, 2026

news preview

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).

news source

Benzinga • Oct 26, 2026

news preview

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

news source

Seeking Alpha • Oct 26, 2026

news preview

Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway

Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement toward FDA Accelerated Approval discussions in 1H 2027 and a phase 3 trial by late 2027. The company is expanding XmAb819 into other ENPP3+ solid tumors and progressing XmAb942 in phase 2b for ulcerative colitis, with interim data expected by end of 2026.

news source

Seeking Alpha • Oct 26, 2026

news preview

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comp.

news source

Business Wire • Oct 25, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Xencor Inc.

Open an M1 investment account to buy and sell Xencor Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in XNCR on M1